Indications for Cefaclor Extended-Release:
Susceptible mild to moderate infections including acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structures.
Take with meals. Swallow whole. Cefaclor ext-rel tab 500mg twice daily clinically equivalent to caps 250mg three times daily. ≥16yrs: Bronchitis: 500mg every 12 hrs for 7 days. Pharyngitis/tonsillitis: 375mg every 12 hrs for 10 days. Skin and skin structures: 375mg every 12 hrs for 7–10 days.
<16yrs: not recommended.
Cefaclor Extended-Release Warnings/Precautions:
Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Cefaclor Extended-Release Classification:
Cefaclor Extended-Release Interactions:
May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. ER: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.
Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.
Formerly known under the brand names Ceclor CD (ext-rel tabs); Ceclor (caps, susp); Raniclor (caps).